🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Illinois
Clinical trial register · United States · industry-sponsored

Clinical Trials in Illinois, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca110 AbbVie101 Eli Lilly and Company71 Merck Sharp & Dohme LLC63 Novartis Pharmaceuticals60
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Illinois

2480 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
NCT06257693Prostate Adenocarcinoma
DrugEnzalutamide
Alessa Therapeutics Inc.
Phase 1
45
California, Illinois, Louisiana, Maryland, Oregon, South Carolina, Virginia, Wisconsin
2024-06-21
Recruiting
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
NCT06188585Acute Gastrointestinal Bleeding
Medtronic - MITG
Not applicable
278
Connecticut, Illinois, Massachusetts, New Jersey, New York
2024-06-21
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2024-06-20
Recruiting
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
NCT06501196Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia
DrugVenetoclax
BlossomHill Therapeutics
Phase 1
170
California, Florida, Illinois, New York, Ohio, Tennessee, Texas, Washington
2024-06-19
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Alabama, Alaska, Arizona, California, Florida, Georgia, Illinois, Iowa
2024-06-19
Recruiting
Study of SGR-3515 In Participants With Advanced Solid Tumors.
NCT06463340Advanced Solid Tumor
Schrödinger, Inc.
Phase 1
52
Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee
2024-06-18
Active, closed
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
80
Delaware, District of Columbia, Illinois, Wisconsin
2024-06-17
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
DrugsVicadrostat·Empagliflozin
Boehringer Ingelheim
Phase 3
6,712
Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-06-17
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT06557265Lupus Nephritis, Primary Membranous Nephropathy
DrugNKX019
Nkarta, Inc.
Phase 1/2
120
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan
2024-06-13
Recruiting
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128Ulcerative Colitis
DrugsVedolizumab·Tofacitinib
Takeda
Phase 4
60
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky
2024-06-12
Recruiting
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
NCT06285643Parkinson Disease
DrugAAV2-GDNF gene therapy
AskBio Inc
Phase 2
127
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-06-11
Recruiting
Transdermal Compress IDE Study
NCT06134167Prosthesis and Implants
Balmoral Medical company
Not applicable
100
California, Colorado, Illinois, Maryland, New York, Ohio, Pennsylvania
2024-06-11
Recruiting
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964Schizophrenia, Cognitive Impairment
Alto Neuroscience
Phase 2
82
California, Florida, Georgia, Illinois, Maryland, Massachusetts, New York
2024-06-11
Recruiting
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
NCT05037968Degenerative Disc Disease, Spine Fusion, Leg Pain and/or Back Pain
Kuros Biosurgery AG
Not applicable
100
Connecticut, Illinois, Maryland, Michigan, North Carolina, Ohio, Utah, Virginia
2024-06-10
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSac-TMT·Nab-paclitaxel·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
851
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2024-06-10
Recruiting
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421Breast Cancer
Exact Sciences Corporation
Observational
1,800
Alaska, California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky
2024-06-07
Active, closed
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167Head and Neck Squamous Cell Carcinoma
DrugsZanzalintinib·Pembrolizumab
Exelixis
Phase 2/3
600
California, Florida, Georgia, Illinois, Iowa, Missouri, New Hampshire, New Jersey
2024-06-07
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 4
303
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2024-06-06
Recruiting
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
NCT06270316Fabry Disease
UniQure Biopharma B.V.
Phase 1/2
20
Alabama, California, Georgia, Illinois, Minnesota, New York, Ohio, Pennsylvania
2024-06-05
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2024-06-05
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
DrugsBrenetafusp·Opdivo·Relatlimab·Nivolumab
Immunocore Ltd
Phase 3
680
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2024-06-05
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
DrugTirzepatide
Eli Lilly and Company
Phase 3
300
California, Delaware, Idaho, Illinois, Indiana, New York, Texas, Utah
2024-06-03
Recruiting
Personal BP - CAI Study
NCT06492746Blood Pressure
Becton, Dickinson and Company
Not applicable
120
Illinois
2024-06-03
Active, closed
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044Thyroid Eye Disease
DrugAMG 732
Amgen
Phase 1/2
94
Arkansas, California, Florida, Illinois, Massachusetts, Nevada, Pennsylvania, Texas
2024-05-30
Active, closed
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
NCT06106672Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
54
Arizona, California, Connecticut, Florida, Illinois, Kansas, Michigan, Missouri
2024-05-30
Recruiting
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
NCT05861986Muscular Atrophy, Spinal
DrugRisdiplam
Hoffmann-La Roche
Phase 4
28
Arkansas, Colorado, Florida, Georgia, Illinois, Michigan, New York, Pennsylvania
2024-05-30
Active, closed
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731Age Related Macular Degeneration (ARMD)
DrugElamipretide
Stealth BioTherapeutics Inc.
Phase 3
313
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2024-05-30
Active, closed
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
DrugsIbrutinib·Venetoclax
Janssen Research & Development, LLC
Phase 2
333
California, Colorado, Florida, Idaho, Illinois, Iowa, Minnesota, Missouri
2024-05-30
Active, closed
A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM
NCT06167655Headache Migraine Chronic
ShiraTronics
Not applicable
250
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-05-29
Recruiting
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
NCT06366789AML With Gene Mutations
Lomond Therapeutics Holdings, Inc.
Phase 1
150
California, Georgia, Illinois, Kansas, Maryland, New York, North Carolina, Ohio
2024-05-29
Active, closed
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
DrugsAnvumetostat·Modified FOLFIRINOX·RMC-6236·Nab-paclitaxel
Amgen
Phase 1
120
California, Colorado, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Missouri
2024-05-29
Recruiting
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT06419634Acute Myeloid Leukemia, Myelodysplastic Syndrome
DrugsAzacitidine·Venetoclax
Bristol-Myers Squibb
Phase 1
105
Connecticut, Illinois, Massachusetts, Missouri, New Jersey, New York, Texas, Virginia
2024-05-29
Active, closed
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
DrugAficamten
Cytokinetics
Phase 2/3
65
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Michigan
2024-05-29
Recruiting
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464Prader-Willi Syndrome
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
134
California, Colorado, Delaware, Georgia, Illinois, Indiana, Maryland, Minnesota
2024-05-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-05-24
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
DrugsCalderasib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
600
California, Connecticut, Florida, Illinois, Missouri, Montana, New Jersey, New York
2024-05-24
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
DrugsBBO-10203·Pembrolizumab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan
2024-05-22
Active, closed
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
NCT06336291Glioblastoma
DrugsL19TNF·Lomustine
Philogen S.p.A.
Phase 2
90
Illinois, Massachusetts, New York, Pennsylvania, Texas, Virginia
2024-05-22
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210Small Cell Lung Cancer
DrugsAmrubicin·Lurbinectedin·Ifinatamab Deruxtecan·Topotecan
Daiichi Sankyo
Phase 3
540
Arkansas, California, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2024-05-21
Active, closed
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
1,456
Alabama, California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas
2024-05-21
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
550
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2024-05-21
Active, closed
A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571Acute Myeloid Leukemias
DrugRevumenib
Syndax Pharmaceuticals
Phase 1
96
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2024-05-21
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2024-05-20
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2024-05-20
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor
AbbVie
Phase 3
421
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana
2024-05-19
Active, closed
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
NCT06393712Cerebral Amyloid Angiopathy
DrugAln-App
Alnylam Pharmaceuticals
Phase 2
210
California, Colorado, Connecticut, Florida, Illinois, Kentucky, Louisiana, Massachusetts
2024-05-17
Recruiting
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
NCT06116110Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma
Miltenyi Biomedicine GmbH
Observational
150
Arizona, California, Connecticut, Illinois, Kansas, Maryland, Massachusetts, North Carolina
2024-05-15
Recruiting
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
NCT06055439Neuroendocrine Tumors, Colorectal Cancer, Gastric Cancer
Chimeric Therapeutics
Phase 1/2
135
Georgia, Illinois, Pennsylvania, Tennessee
2024-05-15
Recruiting
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
NCT05419492Dravet Syndrome
DrugETX101
Encoded Therapeutics
Phase 1/2
47
California, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina
2024-05-14
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugPembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, Michigan, Missouri
2024-05-14
Recruiting
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964Bipolar Depression
DrugLumateperone
Intra-Cellular Therapies, Inc.
Phase 3
384
Alabama, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-05-14
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
858 Therapeutics, Inc.
Phase 1/2
120
Arizona, Connecticut, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio
2024-05-13
Recruiting
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
NCT06349473Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency
DrugSR604
Equilibra Bioscience LLC
Phase 1
31
California, Illinois, Louisiana, Michigan, Missouri, North Carolina, Pennsylvania
2024-05-10
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2024-05-08
By invitation
Long Term Follow-up for RGX-202
NCT06491927Duchenne Muscular Dystrophy
REGENXBIO Inc.
Observational
66
Arkansas, California, Illinois, Texas, Virginia
2024-05-08
Recruiting
Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
NCT06218875AAA - Abdominal Aortic Aneurysm
W.L.Gore & Associates
Observational
2,000
Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana
2024-05-07
Recruiting
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
NCT06138639Duchenne Muscular Dystrophy
Solid Biosciences Inc.
Phase 1/2
60
Arkansas, California, Georgia, Illinois, Missouri, Ohio, Oregon, Pennsylvania
2024-05-06
Active, closed
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
NCT05973487Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
TScan Therapeutics, Inc.
Phase 1
840
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2024-05-06
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, North Dakota
2024-05-03
Active, closed
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes
Endogenex, Inc.
Not applicable
350
Alabama, California, Florida, Illinois, Iowa, Maryland, Minnesota, New Jersey
2024-05-01
Active, closed
Investigation of the Effects of a Bifidobacterial Strain on Bowel Movement in Healthy Adults
NCT06686420Infrequent Bowel Movements
Morinaga Milk Industry Co., LTD
Not applicable
80
Illinois
2024-05-01
By invitation
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
NCT06431893Homocystinuria
DrugPegtibatinase
Travere Therapeutics, Inc.
Phase 3
100
Arizona, Connecticut, Georgia, Illinois, Maine, Maryland, New York, North Carolina
2024-04-30
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugLY3650150
Eli Lilly and Company
Phase 3
510
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-04-29
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2024-04-29
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Osimertinib
AstraZeneca
Phase 3
582
California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maryland
2024-04-29
Recruiting
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
NCT06345339Hypothyroidism
DrugLevothyroxine
AbbVie
Phase 2/3
2,800
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2024-04-26
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLY3650150
Eli Lilly and Company
Phase 3
450
California, Colorado, Florida, Illinois, Kentucky, Michigan, Minnesota, Missouri
2024-04-26
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Carboplatin·Pembrolizumab·Paclitaxel
Janssen Research & Development, LLC
Phase 1/2
287
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Missouri
2024-04-22
Active, closed
A Central Preservation and Assessment Service to Optimize Donor Kidney Allocation
NCT06263023Organ Preservation
34 Lives, PBC
Observational
80
Illinois, Indiana, Missouri, New York, North Carolina, Wisconsin
2024-04-19
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Arkansas, California, Colorado, Florida, Illinois, Indiana, Kansas, Louisiana
2024-04-18
Recruiting
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754Crohn's Disease
DrugsUstekinumab·Adalimumab·Vedolizumab
Takeda
Phase 4
50
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2024-04-18
Active, closed
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06253221Cardiomyopathy, Hypertrophic
DrugMavacamten
Bristol-Myers Squibb
Phase 3
44
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-04-17
Active, closed
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935Crohn's Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
120
California, Illinois, Missouri, South Carolina
2024-04-17
Recruiting
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
NCT06192576Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
Sanofi
Observational
10
Illinois, Ohio, Pennsylvania, Texas, Utah
2024-04-16
Active, closed
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
NCT06372496Asthma
GlaxoSmithKline
Phase 4
1,366
Alabama, Arkansas, California, Delaware, Florida, Illinois, Louisiana, Maine
2024-04-16
By invitation
Pivotal Trial of the Boomerang Catheter for pDVA
NCT06311773Chronic Limb-Threatening Ischemia
Aveera Medical, Inc.
Not applicable
120
California, Delaware, Florida, Illinois, Louisiana, Massachusetts, New Hampshire, New Jersey
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-04-16
Active, closed
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
NCT06155500Sickle Cell Disease
Novartis Pharmaceuticals
Phase 1
4
Illinois, New York, Tennessee
2024-04-16
Recruiting
The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).
NCT02998229Intracranial Aneurysm
Medtronic Neurovascular Clinical Affairs
Not applicable
300
California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts
2024-04-16
Active, closed
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
NCT06192758Prostate, Cancer
Boston Scientific Corporation
Not applicable
36
Illinois
2024-04-15
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
DrugsLiposomal doxorubicin·Sacituzumab tirumotecan·Nab-paclitaxel·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,200
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2024-04-14
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-04-12
Active, closed
A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750Prurigo Nodularis
DrugBarzolvolimab
Celldex Therapeutics
Phase 2
140
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2024-04-12
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Dato-DXd·Rilvegostomig·Pembrolizumab
AstraZeneca
Phase 3
675
Alaska, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2024-04-11
Recruiting
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06236438Non-Small Cell Lung Cancer
DrugsLivmoniplimab·Budigalimab·Pemetrexed·Cisplatin
AbbVie
Phase 2/3
840
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri
2024-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
California, Illinois, Minnesota, New York, Tennessee, Texas, Utah, Virginia
2024-04-10
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
DrugsTAR-200·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
272
Arkansas, California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan
2024-04-09
Recruiting
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
NCT06255782Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
iECURE, Inc.
Phase 3
20
California, Colorado, Georgia, Illinois, New York, Oregon
2024-04-08
Active, closed
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Hernia Surgery (Enable Hernia Repair)
NCT06445504Inguinal Hernia, Ventral Hernia
Medtronic - MITG
Not applicable
206
Florida, Illinois, New York, North Carolina, Ohio, Texas, Virginia
2024-04-08
Active, closed
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
NCT06029660Aortic Aneurysm, Abdominal
Shape Memory Medical, Inc.
Not applicable
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Maine
2024-04-05
Recruiting
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
NCT06316297Acne
DrugAcne mRNA vaccine
Sanofi Pasteur, a Sanofi Company
Phase 1/2
800
Arizona, California, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky
2024-04-05
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
DrugXmAb541
Xencor, Inc.
Phase 1
282
California, Florida, Georgia, Illinois, Indiana, Michigan, Minnesota, New Jersey
2024-04-04
Active, closed
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
NCT06073132Generalized Epidermolysis Bullosa Simplex
TWi Biotechnology, Inc.
Phase 2/3
80
California, Colorado, Illinois, Ohio, South Carolina, Texas
2024-04-04
Active, closed
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT06008093Carcinoma, Non-Small-Cell Lung
DrugsTremelimumab·Durvalumab·Pemetrexed·Cisplatin
AstraZeneca
Phase 2
103
California, District of Columbia, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts
2024-04-04
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Gemcitabine·Pemetrexed·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
780
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-04-03
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
Avalyn Pharma Inc.
Phase 2
375
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-04-03
Active, closed
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
NCT05966194Oral Mucositis
DrugsRRx-001·Cisplatin
EpicentRx, Inc.
Phase 2
216
Arizona, Florida, Illinois, Indiana, Louisiana, Maryland, Michigan, Nevada
2024-04-02
Recruiting
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
NCT06265727Solid Tumor, Adult
DrugsCRB-701·Anti-PD-1
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Alabama, California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Nebraska
2024-04-01
Active, closed
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151Prostate Cancer, Prostate Adenocarcinoma
Curium US LLC
Phase 3
439
Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Iowa
2024-04-01
By invitation
Clinical Registry Collecting Real World Evidence on Wound Care Treatments
NCT06328010Wounds and Injuries, Burns, Mohs Surgery, Diabetic Foot Ulcer Mixed
Siddhey LLC
Observational
5,000
Arizona, California, Florida, Illinois, Nevada, Texas
2024-04-01
Rows per page Showing 1201–1300 of 2480
Previous 11 12 13 14 15 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/illinois?page=13

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,480 of those studies with a site in Illinois.

How many clinical trials are recruiting in Illinois?

1,263 of the 2,480 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 37 have not yet opened recruitment, 1,117 are active but closed to new participants, and 63 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.